High-dose Dexamethasone Plus Hetrombopag Versus High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia (ITP):A Prospective Multicenter Randomized Trial
Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of Hetrombopag plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Older than 18 years
• Meet the diagnostic criteria for newly diagnosed immune thrombocytopenia (diagnosed within 3 month);
• platelet count \<30\*10\^9/L, or \< 50\*10\^9/L with bleeding manifestations, both;
• Willing and able to sign written informed consent
Locations
Other Locations
China
Shengli Oilfield Central Hospital
RECRUITING
Dongying
Contact Information
Primary
Yan Shi
shiyansjj@163.com
8682169896
Time Frame
Start Date: 2023-09-15
Completion Date: 2024-12-10
Participants
Target number of participants: 100
Treatments
Experimental: Hetrombopag plus High-dose Dexamethasone
Hetrombopag 5mg po qd; HD-DEX 40mg qd for 4 days
Active_comparator: High-dose Dexamethasone
HD-DEX 40mg qd for 4 days
Related Therapeutic Areas
Sponsors
Leads: Shandong University